Neochromosome

Neochromosome

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $35M

Overview

Neochromosome is a San Diego-based biotech firm leveraging its first-in-class platform for designing, building, and testing synthetic eukaryotic genomes. Founded in 2014 and now a subsidiary of Opentrons Labworks, it offers services ranging from complex DNA synthesis to full chromosome assembly and delivery. The company targets partners in therapeutics and industrial biotechnology, aiming to enable cell-based manufacturing with custom-designed genomes.

Genetics & Genomics

Technology Platform

A vertically integrated platform for genome-scale engineering, including highly automated complex DNA synthesis, locus-scale genome rewriting/verification, and de novo design, synthesis, and delivery of entire chromosomes. Leverages robotics from parent company Opentrons for a scalable 'genome foundry'.

Funding History

1
Total raised:$35M
Series A$35M

Opportunities

The company is positioned to capitalize on the growing demand for complex genetic engineering in cell/gene therapy and industrial biomanufacturing.
Its unique ability to synthesize and deliver chromosome-scale DNA could make it a critical enabler for next-generation therapeutics and sustainable production platforms.

Risk Factors

Key risks include the nascent market for whole-chromosome engineering services, competition from large DNA synthesis and gene editing companies, and technical execution challenges in highly complex projects.
Financial and strategic dependency on its parent company, Opentrons Labworks, is also a factor.

Competitive Landscape

Neochromosome competes with large DNA synthesis providers (e.g., Twist Bioscience) and gene editing firms, but its differentiation lies in the scale and integration of its platform for full chromosome design and assembly. It occupies a specialized niche between traditional gene synthesis and whole-genome engineering.